Locally Advanced Pancreatic Cancer: Current Therapeutic Approach
TEST_code
|
CME Activity Information |
|
Release Date: |
June 22, 2006 |
|
Most Recent Review: |
June 12, 2007* |
|
Most Recent Update: |
June 22, 2006 |
|
Date Credit Expires: |
June 22, 2008 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by June 22, 2008, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in gastrointestinal cancer and are involved in providing patient care in a cancer
care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Discuss the natural history of locally advanced pancreatic cancer, compared
with resectable or metastatic pancreatic cancer.
- Describe the palliative management of obstruction, celiac plexus pain, and
bleeding.
- Evaluate various combinations of chemotherapy and radiation.
- Discuss new strategies to manage locally advanced pancreatic cancer.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the National Institutes
of Health Foundation for Advance Education in the Sciences (NIH/FAES) and The
Oncologist. The NIH/FAES is accredited by the ACCME to provide continuing
medical education for physicians.
The NIH/FAES designates this educational activity for a maximum of 1.00 AMA
PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the NIH/FAES
to ensure balance, independence, objectivity, and scientific rigor in all of its
educational activities and to include information free of commercial bias and
based on the best evidence available. All individuals in a position to influence
the content of this activity have disclosed relevant financial interests or relationships
of their own, their spouse/partner, or their worksite, with manufacturers or providers
of commercial products, services, technology, or programs; and disclosed relationships
with current non-governmental supporters of the activity. The faculty and planners
have indicated that they have no relevant commercial relationships. For a list
of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml.
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Author Disclosure(s)
Higinia R. Cardenes, M.D., Ph.D.
Credentials: Department of Radiation Oncology,Indiana University
School of Medicine, Indianapolis, Indiana, USA. Telephone:
317-274-2524; Fax: 317-274-2486; E-mail: hcardane{at}iupui.edu.
Disclosures: The author has received support for a clinical
trial on pancreatic cancer from Genentech.
Elena G. Chiorean, M.D.
Credentials: Department of Medical Oncology, Indiana University
School of Medicine, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the
unlabeled, investigational, or alternative use(s) of Genentech's bevacizumab
and ImClone's cetuximab for a pancreatic cancer clinical trial.
John DeWitt, M.D.
Credentials: Department of Gastroenterology, Indiana University
School of Medicine, Indianapolis, Indiana, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Max Schmidt, M.D., Ph.D.
Credentials: Department of Surgery, Indiana University
School of Medicine, Indianapolis, Indiana, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Patrick Loehrer, M.D.
Credentials: Department of Medical Oncology, Indiana University
School of Medicine, Indianapolis, Indiana, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Commercial Support
Non-governmental supporters of this activity: Bristol-Myers
Squibb Oncology and sanofi-aventis
Other Links
System requirements
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
View this course
EXPIRED
Copyright © 2008 by AlphaMed Press.